Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus 65 kDa phosphoprotein (pp65)
- Target
- pp65
- Molecular classification
- Viral tegument protein, Structural protein, Viral phosphoprotein
01
Overview
The Human cytomegalovirus 65 kDa phosphoprotein (pp65, encoded by the UL83 gene) is one of the most abundant structural proteins in HCMV virions, localizing predominantly in the tegument. It is not essential for viral replication in cultured fibroblasts but plays key roles in virion assembly, structural integrity, and the modulation of host immune responses by hindering host interferon regulatory factor 3 (IRF3) activity[1][3][7]. pp65 acts as a dominant target for antiviral T cell responses and is widely used in diagnosis and immune monitoring of HCMV infection. While it does not serve as the direct molecular target for currently approved antiviral drugs, it remains a focus for immunotherapeutic and vaccine development[4][6][7].
- Other names
- UL83ppUL83HCMV pp65
02
Mechanism of action
Drugs do not directly target pp65; immunotherapeutic approaches utilize pp65-derived peptides to stimulate T cell responses against infected cells\nInteracts with and is phosphorylated by the HCMV protein kinase UL97, which is targeted by antivirals like maribavir
03
Biological functions
Viral immune evasionStructural scaffold in virion assemblyRegulation of virion morphogenesisInterference with host interferon response
04
Disease associations
Infection (cytomegalovirus disease, particularly in immunocompromised patients)
05
Safety considerations
No direct drug safety concerns; antigen-based immunotherapies must monitor for off-target immune activation
06
Interacting drugs
None approved as direct drugs, but pp65 is a major antigenic target in immunotherapy and diagnostic assays
07
Biomarkers
Used as a biomarker in immune monitoring (detection of pp65-specific T cells)Used in diagnostic assays for active HCMV infection (antigenemia assays)
Beyond the preview
Go deeper on Human cytomegalovirus 65 kDa phosphoprotein (pp65).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human cytomegalovirus 65 kDa phosphoprotein (pp65).